Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer

Oncology Letters

Volumn 11, Issue 6, 2016, Pages 3643-3649

  Tamura, Kenji ^a   Hazama, Shoichi ^b   Yamaguchi, Rui ^c   Imoto, Seiya ^c   Takenouchi, Hiroko ^b   Inoue, Yuka ^b   Kanekiyo, Shinsuke ^b   Shindo, Yoshitaro ^b   Miyano, Satoru ^c   Nakamura, Yusuke ^a   Kiyotani, Kazuma ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clonotype; Colorectal cancer; Diversity; Predictive biomarker; T cell receptor repertoire; TCR ; TCR

Indexed keywords

MESSENGER RNA; OXALIPLATIN; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CELL POPULATION; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RNA EXTRACTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84966728696     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4465     Document Type: Article

References (28)

1. Zitvogel L, Kepp O and Kroemer G: Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8: 151-160, 2011.
2. Zitvogel L, Galluzzi L, Smyth MJ and Kroemer G: Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity 39: 74-88, 2013.
3. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al: Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 353: 2654-2666, 2005.
4. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006.
5. Laghi L, Bianchi P, Miranda E, et al: CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: A longitudinal study. Lancet Oncol 10: 877-884, 2009.
6. Fridman WH, Pagès F, Sautes-Fridman C and Galon J: The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer 12: 298-306, 2012.
7. Yasuda K, Nirei T, Sunami E, Nagawa H and Kitayama J: Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol 6: 49, 2011.
8. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10: 909-915, 2004.
9. Gajewski TF, Schreiber H and Fu YX: Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14: 1014-1022, 2013.
10. Poggi A, Musso A, Dapino I and Zocchi MR: Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells. Immunol Lett 159: 55-72, 2014.
11. Janeway CA Jr, Travers P, Walport M and Shlomchik MJ: Immunobiology: The Immune System in Health and Disease. 5th edition. Garland Science, New York, 2001.
12. Morris GP and Allen PM: How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nat Immunol 13: 121-128, 2012.
13. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J and Kourilsky P: A direct estimate of the human alphabeta T cell receptor diversity. Science 286: 958-961, 1999.
14. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J and Kourilsky P: Diversity of human alpha beta T cell receptors. Science 288: 1135, 2000.
15. Thor Straten P, Schrama D, Andersen MH and Becker JC: T-cell clonotypes in cancer. J Transl Med 2: 11, 2004.
16. Hazama S, Nakamura Y, Tanaka H, Hirakawa K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, et al: A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med 12: 108, 2014.
17. Fang H, Yamaguchi R, Liu X, Daigo Y, Yew PY, Tanikawa C, Matsuda K, Imoto S, Miyano S and Nakamura Y: Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS). Oncoimmunology 3: e968467, 2015.
18. Giudicelli V, Chaume D and Lefranc MP: IMGT/GENE-DB: A comprehensive database for human and mouse immunoglobulin and T cell receptor genes. Nucleic Acids Res 33: D256-D261, 2005.
19. Langmead B and Salzberg SL: Fast gapped-read alignment with Bowtie 2: Nat Methods 9: 357-359, 2012.
20. Yousfi Monod M, Giudicelli V, Chaume D and Lefranc MP: IMGT/JunctionAnalysis: The first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 20 (Suppl 1): S379-S385, 2004.
21. Venturi V, Kedzierska K, Turner SJ, Doherty PC and Davenport MP: Methods for comparing the diversity of samples of the T cell receptor repertoire. J Immunol Methods 321: 182-195, 2007.
22. Ochsenreither S, Fusi A, Wojtke S, Busse A, Nüssler NC, Thiel E, Keilholz U and Nagorsen D: Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients. J Transl Med 8: 35, 2010.
23. Sherwood AM, Emerson RO, Scherer D, Habermann N, Buck K, Staffa J, Desmarais C, Halama N, Jaeger D, Schirmacher P, et al: Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother 62: 1453-1461, 2013.
24. Luo W, Liao WJ, Huang YT, Shi M, Zhang Y, Wen Q, Zhou MQ and Ma L: Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy. Cancer Sci 102: 706-712, 2011.
25. Zhou J, Ma R, Luo R, Sun Y, He X, Sun W, Tang W and Yao X: Primary exploration of CDR3 spectratyping and molecular features of TCR β chain in the peripheral blood and tissue of patients with colorectal carcinoma. Cancer Epidemiol 34: 733-740, 2010.
26. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F and Galon J: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29: 610-618, 2011.
27. Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E and Scheibenbogen C: Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 60: 4850-4854, 2000.
28. Czerkinsky C, Andersson G, Ekre HP, et al: Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 110: 29-36, 1988.